Sunder Biomedical Tech Co

Sunder Biomedical Tech Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Sunder Biomedical Tech Co (4115.TWO) as of Oct 27, 2026 is -16.84. In the previous year, Net Debt to Free Cash Flow Ratio was 25.64 — a change of -165.68% (lower).

Net Debt/FCF

-16.84

YoY

-165.68%

Last updated:

Net Debt to Free Cash Flow Ratio of Sunder Biomedical Tech Co is 2025 -16.84 . Net Debt to Free Cash Flow Ratio of Sunder Biomedical Tech Co was 2024 25.64 . It decreases by -165.68% lower compared to the previous year.

The Sunder Biomedical Tech Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2020
-11.66 TWD
Jan 1, 2021
3.84 TWD
Jan 1, 2022
10.35 TWD
Jan 1, 2023
-23.68 TWD
Jan 1, 2024
25.64 TWD
Jan 1, 2025
-16.84 TWD
The Sunder Biomedical Tech Co Net Debt/FCF history
YEARNet Debt/FCFYoY
-16.84-165.68%
25.64-208.28%
-23.68-328.79%
10.35+169.57%
3.84-132.93%
-11.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunder Biomedical Tech Co Stock analysis

What does Sunder Biomedical Tech Co do? Sunder Biomedical Tech Co Ltd manufactures and sells medical consumables including blood circuit catheters, puncture needles, infusion sets, suction tubing, dosing sets, waste fluid collection bags, and protective covers. The company also produces laparoscopic smoke filters, suction sets, pick-up bags, and medical grade materials such as PVC pellets, NON-diethylhexyl phthalate (DEHP) PVC, and other medical components. Additionally, Sunder Biomedical offers sterilization and laboratory services, along with foundry services for masks, tubes, and nucleic acid extraction well tray consumables. The primary buyers of Sunder Biomedical's products are healthcare facilities, hospitals, and medical institutions requiring disposable medical equipment and supplies. These clients purchase medical consumables for routine procedures, surgical operations, and patient care. The company's focus on medical grade materials ensures compliance with healthcare standards, making its products essential for medical professionals. Sunder Biomedical's revenue streams include direct sales of medical consumables, sterilization services, and foundry services for specialized medical components. The company targets the healthcare sector, particularly hospitals and clinics, where demand for reliable, high-quality disposable medical products is consistent. By providing a comprehensive range of medical supplies, Sunder Biomedical caters to the operational needs of healthcare providers across various medical specialties. Sunder Biomedical Tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunder Biomedical Tech Co stock

Net Debt to Free Cash Flow Ratio of Sunder Biomedical Tech Co is -16.84 in 2025.

Net Debt to Free Cash Flow Ratio of Sunder Biomedical Tech Co changed from 25.64 to -16.84, representing a -165.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Sunder Biomedical Tech Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Sunder Biomedical Tech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Sunder Biomedical Tech Co

All Key Metrics — Sunder Biomedical Tech Co